Kura Oncology to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) announced that CEO Troy Wilson will participate in two virtual investor conferences. The events include a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 11:30 a.m. ET, and another at the 2020 Cantor Virtual Global Healthcare Conference on September 16, 2020, at 4:00 p.m. ET. Live webcasts will be accessible on Kura’s website, with archived replays available for 30 days. Kura is focused on precision medicines for cancer, with drug candidates targeting critical pathways in cancer treatment.

SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming virtual investor conferences: 

• A fireside chat at the H.C. Wainwright 22^nd Annual Global Investment Conference on September 15, 2020 at 11:30 a.m. ET / 8:30 a.m. PT; and
  
  
• A fireside chat at the 2020 Cantor Virtual Global Healthcare Conference on September 16, 2020 at 4:00 p.m. ET / 1:00 p.m. PT.

Live audio webcasts of the fireside chats will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available for 30 days following the events.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company’s pipeline is also highlighted by KO-539, a potent and selective inhibitor of the menin-KMT2A(MLL) protein-protein interaction currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed/refractory acute myeloid leukemia. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com

FAQ

What events is Kura Oncology participating in September 2020?

Kura Oncology will participate in the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, and the 2020 Cantor Virtual Global Healthcare Conference on September 16, 2020.

Who is presenting for Kura at the investor conferences?

Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology, will present at the conferences.

Where can I watch Kura Oncology's conference presentations?

Live webcasts of Kura Oncology’s presentations will be available in the Investors section of their website.

What is Kura Oncology's focus in cancer treatment?

Kura Oncology is focused on developing precision medicines for cancer, with drug candidates targeting specific cancer signaling pathways.

What are Kura's main drug candidates?

Kura's main drug candidates include tipifarnib for head and neck cancer and KO-539 for acute myeloid leukemia.

How long will Kura’s conference replays be available?

The archived replays of Kura's conference presentations will be available for 30 days after the events.